(TGTX) TG Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US88322Q1085
Stock: Antibodies, Cancer Treatments, Blood Disorders
Total Rating 21
Risk 32
Buy Signal -0.83
| Risk 5d forecast | |
|---|---|
| Volatility | 54.9% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.58 |
| Alpha | -39.75 |
| Character TTM | |
|---|---|
| Beta | 0.791 |
| Beta Downside | -0.571 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.91% |
| CAGR/Max DD | 0.33 |
EPS (Earnings per Share)
Revenue
Description: TGTX TG Therapeutics March 05, 2026
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases. The companys primary commercial product is BRIUMVI, an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis (RMS).
The biotechnology sector is characterized by extensive research and development, often requiring significant capital investment and long development cycles for new drugs. TGTXs pipeline includes Ublituximab IV for RMS, TG-1701 (a BTK inhibitor), and TG-1801 (a bispecific antibody), indicating a focus on both commercialization and ongoing drug discovery.
The companys business model involves both internal drug development and strategic licensing and collaboration agreements. Biopharmaceutical companies frequently leverage such partnerships to expand their development capabilities and market reach, particularly for specialized treatments like those targeting hematological malignancies.
For further in-depth analysis of TGTXs financial performance and market position, consider exploring ValueRay.
Headlines to watch out for
- BRIUMVI sales growth drives revenue
- Pipeline development success impacts future valuation
- Regulatory approvals for new indications crucial
- Competition in MS market affects market share
- Licensing agreements provide revenue and development support
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 447.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 4.67 > 1.0 |
| NWC/Revenue: 77.40% < 20% (prev 144.6%; Δ -67.18% < -1%) |
| CFO/TA -0.02 > 3% & CFO -24.8m > Net Income 447.2m |
| Net Debt (181.6m) to EBITDA (134.4m): 1.35 < 3 |
| Current Ratio: 4.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.4m) vs 12m ago -0.55% < -2% |
| Gross Margin: 83.64% > 18% (prev 0.88%; Δ 8.28k% > 0.5%) |
| Asset Turnover: 75.11% > 50% (prev 56.95%; Δ 18.16% > 0%) |
| Interest Coverage Ratio: 5.02 > 6 (EBITDA TTM 134.4m / Interest Expense TTM 26.7m) |
Altman Z'' -2.01
| A: 0.45 (Total Current Assets 630.8m - Total Current Liabilities 153.8m) / Total Assets 1.06b |
| B: -1.02 (Retained Earnings -1.08b / Total Assets 1.06b) |
| C: 0.16 (EBIT TTM 134.1m / Avg Total Assets 820.5m) |
| D: -2.61 (Book Value of Equity -1.08b / Total Liabilities 415.2m) |
| Altman-Z'' Score: -2.01 = D |
Beneish M 1.00
| DSRI: 1.26 (Receivables 305.6m/129.2m, Revenue 616.3m/329.0m) |
| GMI: 1.06 (GM 83.64% / 88.28%) |
| AQI: 55.40 (AQ_t 0.40 / AQ_t-1 0.01) |
| SGI: 1.87 (Revenue 616.3m / 329.0m) |
| TATA: 0.44 (NI 447.2m - CFO -24.8m) / TA 1.06b) |
| Beneish M-Score: 30.58 (Cap -4..+1) = D |
What is the price of TGTX shares?
As of March 21, 2026, the stock is trading at USD 30.36 with a total of 3,314,188 shares traded.
Over the past week, the price has changed by +12.69%, over one month by +3.05%, over three months by -2.00% and over the past year by -28.51%.
Over the past week, the price has changed by +12.69%, over one month by +3.05%, over three months by -2.00% and over the past year by -28.51%.
Is TGTX a buy, sell or hold?
TG Therapeutics has received a consensus analysts rating of 4.43.
Therefore, it is recommended to buy TGTX.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.4 | 46.3% |
| Analysts Target Price | 44.4 | 46.3% |
TGTX Fundamental Data Overview March 19, 2026
P/E Trailing = 11.3755
P/E Forward = 23.753
P/S = 8.1647
P/B = 7.0896
P/EG = 1.6144
Revenue TTM = 616.3m USD
EBIT TTM = 134.1m USD
EBITDA TTM = 134.4m USD
Long Term Debt = 245.6m USD (from longTermDebt, last quarter)
Short Term Debt = 1.04m USD (from shortTermDebt, last quarter)
Debt = 260.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 181.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.15b USD (5.03b + Debt 260.7m - CCE 142.0m)
Interest Coverage Ratio = 5.02 (Ebit TTM 134.1m / Interest Expense TTM 26.7m)
EV/FCF = -206.1x (Enterprise Value 5.15b / FCF TTM -25.0m)
FCF Yield = -0.49% (FCF TTM -25.0m / Enterprise Value 5.15b)
FCF Margin = -4.05% (FCF TTM -25.0m / Revenue TTM 616.3m)
Net Margin = 72.56% (Net Income TTM 447.2m / Revenue TTM 616.3m)
Gross Margin = 83.64% ((Revenue TTM 616.3m - Cost of Revenue TTM 100.8m) / Revenue TTM)
Gross Margin QoQ = 80.16% (prev 82.59%)
Tobins Q-Ratio = 4.84 (Enterprise Value 5.15b / Total Assets 1.06b)
Interest Expense / Debt = 2.51% (Interest Expense 6.53m / Debt 260.7m)
Taxrate = 48.91% (22.1m / 45.1m)
NOPAT = 68.5m (EBIT 134.1m * (1 - 48.91%))
Current Ratio = 4.10 (Total Current Assets 630.8m / Total Current Liabilities 153.8m)
Debt / Equity = 0.40 (Debt 260.7m / totalStockholderEquity, last quarter 648.0m)
Debt / EBITDA = 1.35 (Net Debt 181.6m / EBITDA 134.4m)
Debt / FCF = -7.27 (negative FCF - burning cash) (Net Debt 181.6m / FCF TTM -25.0m)
Total Stockholder Equity = 442.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 54.50% (Net Income 447.2m / Total Assets 1.06b)
RoE = 101.1% (Net Income TTM 447.2m / Total Stockholder Equity 442.2m)
RoCE = 19.50% (EBIT 134.1m / Capital Employed (Equity 442.2m + L.T.Debt 245.6m))
RoIC = 10.94% (NOPAT 68.5m / Invested Capital 626.2m)
WACC = 8.46% (E(5.03b)/V(5.29b) * Re(8.83%) + D(260.7m)/V(5.29b) * Rd(2.51%) * (1-Tc(0.49)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 5.53%
[DCF] Fair Price = unknown (Cash Flow -25.0m)
EPS Correlation: 62.84 | EPS CAGR: 150.4% | SUE: -0.24 | # QB: 0
Revenue Correlation: 81.74 | Revenue CAGR: 237.3% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=-0.003 | Chg30d=-0.056 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=1.24 | Chg7d=-0.013 | Chg30d=-0.377 | Revisions Net=-1 | Growth EPS=-55.1% | Growth Revenue=+45.6%
EPS next Year (2027-12-31): EPS=2.46 | Chg7d=-0.033 | Chg30d=+0.023 | Revisions Net=-1 | Growth EPS=+98.1% | Growth Revenue=+26.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.0% (Discount Rate 8.8% - Earnings Yield 8.8%)
[Growth] Growth Spread = +52.5% (Analyst 52.6% - Implied 0.0%)
P/E Forward = 23.753
P/S = 8.1647
P/B = 7.0896
P/EG = 1.6144
Revenue TTM = 616.3m USD
EBIT TTM = 134.1m USD
EBITDA TTM = 134.4m USD
Long Term Debt = 245.6m USD (from longTermDebt, last quarter)
Short Term Debt = 1.04m USD (from shortTermDebt, last quarter)
Debt = 260.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 181.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.15b USD (5.03b + Debt 260.7m - CCE 142.0m)
Interest Coverage Ratio = 5.02 (Ebit TTM 134.1m / Interest Expense TTM 26.7m)
EV/FCF = -206.1x (Enterprise Value 5.15b / FCF TTM -25.0m)
FCF Yield = -0.49% (FCF TTM -25.0m / Enterprise Value 5.15b)
FCF Margin = -4.05% (FCF TTM -25.0m / Revenue TTM 616.3m)
Net Margin = 72.56% (Net Income TTM 447.2m / Revenue TTM 616.3m)
Gross Margin = 83.64% ((Revenue TTM 616.3m - Cost of Revenue TTM 100.8m) / Revenue TTM)
Gross Margin QoQ = 80.16% (prev 82.59%)
Tobins Q-Ratio = 4.84 (Enterprise Value 5.15b / Total Assets 1.06b)
Interest Expense / Debt = 2.51% (Interest Expense 6.53m / Debt 260.7m)
Taxrate = 48.91% (22.1m / 45.1m)
NOPAT = 68.5m (EBIT 134.1m * (1 - 48.91%))
Current Ratio = 4.10 (Total Current Assets 630.8m / Total Current Liabilities 153.8m)
Debt / Equity = 0.40 (Debt 260.7m / totalStockholderEquity, last quarter 648.0m)
Debt / EBITDA = 1.35 (Net Debt 181.6m / EBITDA 134.4m)
Debt / FCF = -7.27 (negative FCF - burning cash) (Net Debt 181.6m / FCF TTM -25.0m)
Total Stockholder Equity = 442.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 54.50% (Net Income 447.2m / Total Assets 1.06b)
RoE = 101.1% (Net Income TTM 447.2m / Total Stockholder Equity 442.2m)
RoCE = 19.50% (EBIT 134.1m / Capital Employed (Equity 442.2m + L.T.Debt 245.6m))
RoIC = 10.94% (NOPAT 68.5m / Invested Capital 626.2m)
WACC = 8.46% (E(5.03b)/V(5.29b) * Re(8.83%) + D(260.7m)/V(5.29b) * Rd(2.51%) * (1-Tc(0.49)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 5.53%
[DCF] Fair Price = unknown (Cash Flow -25.0m)
EPS Correlation: 62.84 | EPS CAGR: 150.4% | SUE: -0.24 | # QB: 0
Revenue Correlation: 81.74 | Revenue CAGR: 237.3% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=-0.003 | Chg30d=-0.056 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=1.24 | Chg7d=-0.013 | Chg30d=-0.377 | Revisions Net=-1 | Growth EPS=-55.1% | Growth Revenue=+45.6%
EPS next Year (2027-12-31): EPS=2.46 | Chg7d=-0.033 | Chg30d=+0.023 | Revisions Net=-1 | Growth EPS=+98.1% | Growth Revenue=+26.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.0% (Discount Rate 8.8% - Earnings Yield 8.8%)
[Growth] Growth Spread = +52.5% (Analyst 52.6% - Implied 0.0%)